CARL ZEISS MEDITEC ADR 1 (AFXA) - Total Liabilities
Based on the latest financial reports, CARL ZEISS MEDITEC ADR 1 (AFXA) has total liabilities worth €1.28 Billion EUR (≈ $1.49 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of CARL ZEISS MEDITEC ADR 1 to evaluate the company's liquid asset resilience ratio.
CARL ZEISS MEDITEC ADR 1 - Total Liabilities Trend (2022–2025)
This chart illustrates how CARL ZEISS MEDITEC ADR 1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CARL ZEISS MEDITEC ADR 1 total assets.
CARL ZEISS MEDITEC ADR 1 Competitors by Total Liabilities
The table below lists competitors of CARL ZEISS MEDITEC ADR 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Heungkong Holding Co Ltd
SHG:600162
|
China | CN¥10.77 Billion |
|
The Great Eastern Shipping Company Limited
NSE:GESHIP
|
India | Rs25.18 Billion |
|
CENTRAL PUERTO ADR/1 AP1
F:C3TA
|
Germany | €1.05 Trillion |
|
SolarEdge Technologies Inc
NASDAQ:SEDG
|
USA | $1.85 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥2.80 Billion |
|
Trevi Therapeutics Inc
NASDAQ:TRVI
|
USA | $9.01 Million |
|
Pandox AB (publ)
ST:PNDX-B
|
Sweden | Skr78.83 Billion |
|
Shenzhen Expressway Co Ltd
SHG:600548
|
China | CN¥38.42 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down CARL ZEISS MEDITEC ADR 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AFXA equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CARL ZEISS MEDITEC ADR 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CARL ZEISS MEDITEC ADR 1 (2022–2025)
The table below shows the annual total liabilities of CARL ZEISS MEDITEC ADR 1 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | €1.28 Billion ≈ $1.49 Billion |
-4.57% |
| 2024-09-30 | €1.34 Billion ≈ $1.56 Billion |
+55.43% |
| 2023-09-30 | €860.02 Million ≈ $1.01 Billion |
+8.49% |
| 2022-09-30 | €792.73 Million ≈ $926.78 Million |
-- |
About CARL ZEISS MEDITEC ADR 1
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for ret… Read more